, a maker of electrical implants to treat neurological disorders such as epilepsy, posted a second-quarter loss of $6.8 million, or 32 cents a share, beating the Wall Street's consensus expectation by 14 cents. In the year-ago period, the company lost $4.9 million, or 26 cents a share.

According to Thomson Financial/First Call, analysts were expecting a loss of 46 cents a share.

Net sales for the quarter were $16.9 million, a 20.5% increase over last year due to strong growth for products that treat epilepsy.